Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Quadrivalent human papillo-mavirus recombinant vaccine

Nature Reviews Drug Discovery volume 5, pages 629–630 (2006)Cite this article

In June 2006, a quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil; Merck) was approved by the US FDA for the prevention of several diseases, including cervical cancer, that are caused by these types of human papillomavirus.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev. Cancer 2, 342–350 (2002).

    Article  CAS  Google Scholar 

  2. Lowy, D. R. & Schiller, J. T. Prophylactic human papillo-mavirus vaccines. J. Clin. Invest. 116, 1167–1173 (2006).

    Article  CAS  Google Scholar 

  3. Kirnbauer, R. et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89, 12180–12184 (1992).

    Article  CAS  Google Scholar 

  4. Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645–1651 (2002).

    Article  CAS  Google Scholar 

  5. Villa, L. L. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6, 271–278 (2005).

    Article  Google Scholar 

  6. Villa, L. L. et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24, 5571–5583 (2006).

    Article  CAS  Google Scholar 

  7. FDA labelling information [online] (2006).

Download references

Author information

Authors and Affiliations

  1. the Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, 02115, Massachusetts, USA

    Christopher Crum

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Carole Jones

  3. Nature Reviews Drug Discovery.,

    Peter Kirkpatrick

Authors
  1. Christopher Crum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carole Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crum, C., Jones, C. & Kirkpatrick, P. Quadrivalent human papillo-mavirus recombinant vaccine. Nat Rev Drug Discov 5, 629–630 (2006). https://doi.org/10.1038/nrd2117

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2117

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing